DDInter470 DDInter1628
Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the range of 2000-9000. LMWHs have a more predictable response, a greater bioavailability, and a longer anti-Xa half life than unfractionated heparin. Dalteparin can also be safely used in most pregnant women. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Dalteparin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Quinapril
Quinapril {u} (Compound) causes {v} (Side Effect) Thrombocytopenia
Thrombocytopenia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Dalteparin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Venlafaxine
Venlafaxine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Dalteparin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triamterene
Triamterene {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Dalteparin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levomilnacipran
Levomilnacipran {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Dalteparin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Milnacipran
Milnacipran {u} (Compound) downregulates {v} (Gene) TRAPPC3
TRAPPC3 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Dalteparin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levomilnacipran
Levomilnacipran {u} (Compound) downregulates {v} (Gene) TRAPPC3
TRAPPC3 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Dalteparin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levomilnacipran
Levomilnacipran {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Dalteparin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluoxetine
Fluoxetine {u} (Compound) downregulates {v} (Gene) PLK1
PLK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Dalteparin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bismuth subsalicylate
Bismuth subsalicylate {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Dalteparin {u} may lead to a major life threatening interaction when taken with {v} Ticlopidine
Ticlopidine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Dalteparin may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Ruxolitinib (Compound)
Dalteparin may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Dalteparin may cause a moderate interaction that could exacerbate diseases when taken with Triamterene and Triamterene (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Dalteparin may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Dalteparin may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran (Compound) downregulates TRAPPC3 (Gene) and TRAPPC3 (Gene) is downregulated by Ruxolitinib (Compound)
Dalteparin may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran (Compound) downregulates TRAPPC3 (Gene) and TRAPPC3 (Gene) is downregulated by Ruxolitinib (Compound)
Dalteparin may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Ruxolitinib (Compound)
Dalteparin may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine and Fluoxetine (Compound) downregulates PLK1 (Gene) and PLK1 (Gene) is bound by Ruxolitinib (Compound)
Dalteparin may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subsalicylate and Bismuth subsalicylate (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Dalteparin may lead to a major life threatening interaction when taken with Ticlopidine and Ticlopidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)